Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Introduction

Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and its streptococcal-associated subset, PANDAS, represent some of the most challenging clinical presentations in pediatric neuroimmunology. These conditions are characterized by the abrupt onset of obsessive-compulsive symptoms, severe anxiety, emotional lability, tics, cognitive decline, and a constellation of associated neuropsychiatric features—all driven by an underlying neuroinflammatory and autoimmune process targeting the basal ganglia. The 2017 PANS/PANDAS Consortium treatment guidelines, published in the Journal of Child and Adolescent Psychopharmacology, established a multimodal framework encompassing psychiatric and behavioral interventions, infection management, and immunomodulatory therapies (Swedo et al., 2017; Thienemann et al., 2017).

Within this multimodal framework, clinicians and families increasingly seek well-tolerated, mechanistically rational adjuncts—particularly for clients with relapsing-remitting courses, overlapping conditions such as mast cell activation syndrome (MCAS) or postural orthostatic tachycardia syndrome (POTS), and situations where first-line immunomodulation with steroids or intravenous immunoglobulin (IVIG) is not feasible. Low-dose naltrexone (LDN) has emerged as one such candidate.

This article reviews the mechanistic rationale for LDN in PANS/PANDAS, examines the available pediatric safety and efficacy data from related conditions, and outlines practical clinical considerations for integrative practitioners. It is important to state at the outset: as of 2026, there are no large-scale randomized controlled trials of LDN specific to PANS/PANDAS populations. The evidence base consists of mechanistic plausibility, pediatric tolerability data from other inflammatory conditions, and growing anecdotal and observational reports (Leiber & Parker, 2025).

What Is Low-Dose Naltrexone?

Naltrexone is an opioid receptor antagonist approved by the FDA at 50 mg daily for the management of opioid and alcohol use disorders. Low-dose naltrexone refers to the off-label use of naltrexone at doses typically at or below 4.5 mg per day—roughly one-tenth of the standard therapeutic dose. At these substantially lower doses, naltrexone exhibits pharmacological properties that are mechanistically distinct from its effects at full dose (Leiber & Parker, 2025).

The growing body of literature on LDN spans chronic pain, autoimmune conditions, neuroinflammatory disorders, and several pediatric indications. A 2026 narrative review published in Advances in Therapy reviewed 105 studies (including 15 randomized controlled trials) across chronic pain, autoimmune and neuroimmune, gastrointestinal, dermatologic, post-infectious, mental health, and oncology indications, noting that LDN is typically prescribed off-label at doses of 0.5 to 6.0 mg (Gouda et al., 2026).

Mechanistic Rationale for LDN in PANS/PANDAS

The theoretical basis for LDN in PANS/PANDAS rests on three interconnected pharmacological mechanisms, each of which addresses a core pathophysiological feature of these conditions.

Microglial Modulation via TLR4 Antagonism

At low doses, naltrexone binds to Toll-like receptor 4 (TLR4) on microglial cells in the central nervous system. TLR4 is a key innate immune receptor that, when activated, drives microglial polarization toward a pro-inflammatory phenotype with increased production of cytokines including TNF-α, IL-1β, and IL-6. By antagonizing TLR4, LDN dampens this inflammatory cascade, effectively reducing neuroinflammation without broadly suppressing immune function. This mechanism has been described across multiple review articles and preclinical studies, and it is considered the primary anti-inflammatory pathway through which LDN exerts its effects in the central nervous system (Younger et al., 2014; Leiber & Parker, 2025).

In PANS/PANDAS, where autoimmune-mediated basal ganglia inflammation is a central pathological feature, the ability to modulate microglial activation without systemic immunosuppression is particularly appealing—especially in a pediatric population where long-term steroid use or repeated IVIG carries its own risk profile.

Immune Rebalancing and Cytokine Modulation

Beyond its effects on microglia, LDN has been shown to shift cytokine profiles from pro-inflammatory toward anti-inflammatory patterns. The transient opioid receptor blockade induced by LDN (lasting approximately four to six hours when dosed at bedtime) triggers a compensatory upregulation of endogenous opioid production, including met-enkephalin and beta-endorphin. These endogenous opioids modulate immune cell function, including T-cell and natural killer cell activity, contributing to a broader rebalancing of immune tone. For children with PANS/PANDAS whose neuropsychiatric symptoms are driven by misdirected immune activation, this rebalancing effect represents a biologically rational adjunctive approach.

Pain and Sensory Modulation

Many children with PANS/PANDAS report somatic symptoms including headaches, joint pain, and heightened sensory sensitivity. LDN has demonstrated analgesic and sensory-modulatory properties across multiple chronic pain conditions in both adult and pediatric populations. A retrospective analysis of 59 pediatric clients at an outpatient pain clinic found that 26 reported qualitative benefits from LDN, with pain improvement being the most commonly cited outcome (Theriault et al., 2023). This dual benefit—addressing both neuroinflammation and pain—makes LDN a particularly efficient adjunct in the PANS/PANDAS population where somatic and neuropsychiatric symptoms frequently co-occur.

What Does the Evidence Show?

Evidence in PANS/PANDAS Specifically

As of mid-2026, there are no published randomized controlled trials evaluating LDN specifically in PANS or PANDAS populations. The available evidence in this specific context is limited to clinician-reported experience, patient-reported outcomes from support communities, and expert opinion. Within these observational frameworks, reports suggest that a meaningful proportion of clients experience moderate improvement in OCD severity, anxiety, mood dysregulation, and irritability when LDN is added to an existing multimodal protocol. However, a subset of clients reports no discernible benefit, and the absence of controlled data means these observations must be interpreted with appropriate caution.

What can be said with greater confidence is that LDN is increasingly recognized as a reasonable adjunct—not a replacement for antibiotics, immunomodulatory therapy, or evidence-based psychiatric interventions when these are indicated. Its favorable tolerability profile and mechanistic alignment with the neuroinflammatory pathophysiology of PANS/PANDAS support its consideration in appropriate clinical contexts (Leiber & Parker, 2025).

Supporting Pediatric Safety Data from Other Conditions

While PANS/PANDAS-specific data are limited, pediatric safety and tolerability data from other inflammatory conditions provide reassurance:

Pediatric Crohn’s Disease: Smith and colleagues conducted a randomized, placebo-controlled pilot trial in 14 children (mean age 12.3 years) with moderate-to-severe Crohn’s disease. Naltrexone was dosed at 0.1 mg/kg orally, and the study reported significant reduction in Pediatric Crohn’s Disease Activity Index (PCDAI) scores (from 34.2±3.3 to 21.7±3.9, p=0.005) with no serious adverse events. This remains the most rigorous published pediatric LDN safety dataset available (Smith et al., 2013).

Pediatric Chronic Pain: A retrospective chart review from an outpatient pediatric pain clinic evaluated 59 children prescribed LDN between 2018 and 2021. Of these, 26 provided qualitative reports of benefit, most commonly pain improvement. The treatment was generally well-tolerated, with no serious adverse events reported (Theriault et al., 2023).

These datasets—while small—are consistent with the broader adult LDN literature demonstrating a favorable safety profile characterized by mild, transient side effects (most commonly vivid dreams, transient sleep disruption, and occasional headache) and the absence of organ toxicity or immunosuppression at low doses.

Clinical Approach to LDN in PANS/PANDAS

When to Consider LDN

Based on the available mechanistic rationale and clinical experience, LDN may be most appropriately considered in the following scenarios:

• Children with relapsing-remitting PANS/PANDAS who have prominent neuroinflammatory features (persistent OCD, anxiety, irritability, sensory symptoms) despite standard-of-care interventions.

• Cases where first-line immunomodulation (steroids or IVIG) is not feasible, not tolerated, or serves as a bridge between flare episodes.

• Clients with overlapping conditions such as MCAS, POTS, chronic pain, or fatigue, where LDN may offer broader benefit across multiple symptom domains.

When to Exercise Caution or Avoid LDN

• Active opioid use: LDN can precipitate opioid withdrawal or block opioid-mediated analgesia. This includes prescription opioids, tramadol, and opioid-containing cough suppressants.

• Significant hepatic impairment: Naltrexone is hepatically metabolized. While the doses used in LDN are far below the threshold associated with hepatotoxicity at standard doses, caution is warranted in clients with known liver disease.

• Unstable severe psychiatric symptoms: Clients with acute, severe neuropsychiatric decompensation requiring urgent guideline-based immunotherapy should receive first-line interventions before adjunctive LDN is introduced.

Dosing Approach

Pediatric LDN dosing follows a low-start, gradual-titration approach. The weight-based dose of 0.1 mg/kg used in the published pediatric Crohn’s trial offers a reasonable anchor for initiation—equivalent to roughly 0.5 to 1.0 mg nightly in most children—with titration every one to two weeks as tolerated toward a target of 1.5 to 4.5 mg nightly. This ceiling is consistent with the 4.5 mg dose most commonly reported across the broader published LDN literature (Smith et al., 2013; Younger et al., 2014).

Bedtime dosing is standard, as it aligns with the transient opioid receptor blockade and compensatory endorphin upregulation that occurs during sleep. Some clinicians consider split dosing if daytime symptom control is a priority, though evening dosing remains the most widely used protocol.

Compounded formulations—either capsules or flavored liquids—are essential, as commercially available 50 mg naltrexone tablets cannot be accurately divided to achieve low-dose ranges. Clinicians should work with USP <795>-compliant 503A compounding pharmacies to ensure dosing accuracy and quality control.

Monitoring

Clinical monitoring for LDN in PANS/PANDAS should track the symptom domains most relevant to the individual client. Key parameters include OCD and tic severity, mood and emotional regulation, anxiety levels, sleep quality, energy and fatigue, pain complaints, and functional measures such as school attendance and social participation. Side effects are typically mild and self-limited; the most commonly reported include vivid dreams (especially in the first one to two weeks), transient agitation or irritability, and headache. Serious adverse events have not been reported in published pediatric LDN studies at these dose ranges.

Positioning LDN Within a Multimodal PANS/PANDAS Protocol

The 2017 Consortium guidelines establish a clear treatment hierarchy for PANS/PANDAS: psychiatric and behavioral interventions (cognitive-behavioral therapy with exposure and response prevention, SSRIs when indicated), infection management (antibiotics for documented or strongly suspected streptococcal or other triggering infections), and immunomodulatory therapies for moderate-to-severe cases (NSAIDs, corticosteroids, IVIG, and in refractory cases, plasmapheresis or rituximab) (Swedo et al., 2017).

LDN fits naturally within this framework as a low-risk immunomodulatory adjunct positioned alongside, rather than instead of, these established interventions. It is most appropriately viewed as one component of a comprehensive, individualized protocol—not as a standalone therapy and not as a substitute for guideline-directed care when that care is indicated.

For integrative and functional medicine practitioners, LDN’s appeal lies precisely in this profile: mechanistically rational, well-tolerated in pediatric populations, compounded at low cost, and compatible with the multimodal philosophy that characterizes best-practice PANS/PANDAS management.

Bottom Line

Low-dose naltrexone is a biologically plausible, low-risk adjunct for PANS/PANDAS that targets neuroinflammation through TLR4-mediated microglial modulation and immune rebalancing. Pediatric safety data from Crohn’s disease and chronic pain populations are reassuring, and growing clinical experience supports its consideration as part of a multimodal treatment approach. Large-scale randomized trials in PANS/PANDAS populations are needed, and clinicians should frame LDN as an adjunctive tool within a comprehensive protocol—not as a replacement for evidence-based first-line therapies.

For families navigating the complexity of PANS/PANDAS, LDN represents one additional option in a growing integrative toolkit—one that aligns with the neuroinflammatory model of these conditions and carries a favorable risk-benefit profile when prescribed and monitored appropriately.

References

1. Gouda AHK, Aitcheson NEC, Steadman KJ. Low-Dose Naltrexone: What is the Evidence? A Narrative Review. Adv Ther. 2026 Apr 30 (Epub ahead of print). doi:10.1007/s12325-026-03612-5. PMID: 42060160.

2. Leiber KK, Parker RW. Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review. Cureus. 2025;17(3):e81086. doi:10.7759/cureus.81086. PMCID: PMC12017383.

3. Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and Tolerability of Low-Dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease: A Pilot Study. J Clin Gastroenterol. 2013;47(4):339-345. doi:10.1097/MCG.0b013e3182702f2b. PMID: 23188075.

4. Swedo SE, Frankovich J, Murphy TK. Overview of Treatment of Pediatric Acute-Onset Neuropsychiatric Syndrome. J Child Adolesc Psychopharmacol. 2017;27(7):562-565. doi:10.1089/cap.2017.0042. PMID: 28722464.

5. Theriault C, Oyelola O, Zempsky WT. The Efficacy of Low-Dose Naltrexone in Pediatric Chronic Pain: A Retrospective Analysis. J Pain. 2023;24(4 Suppl):84-85 (conference abstract).

6. Thienemann M, Murphy T, Leckman J, et al. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I—Psychiatric and Behavioral Interventions. J Child Adolesc Psychopharmacol. 2017;27(7):566-573. PMCID: PMC5610394.

7. Younger J, Parkitny L, McLain D. The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2. PMID: 24526250.

About Dr. Kim

Dr. Yoon Hang “John” Kim is a board-certified physician with over 20 years of clinical experience in integrative and functional medicine. A graduate of the University of Arizona’s fellowship in Integrative Medicine under Dr. Andrew Weil, Dr. Kim holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with additional certification in medical acupuncture (UCLA). He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books (including the LDN Primer and a clinical LDN textbook) and over 20 peer-reviewed articles.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com